IP Library › Granted Patent US 12,667,576
Granted Patent B2
US 12,667,576 · App. 17/963,502 · Granted Jun 30, 2026

Methods of treating and/or preventing actinic keratosis

Inventors: Min-Fun Rudolf Kwan (Summit, NJ); Johnson Yiu-Nam Lau (Houston, TX); E. Douglas Kramer (Stamford, CT); David Lawrence Cutler (Moorestown, NJ); Jane Fang (Newport Beach, CA)
Assignee: ATNX SPV, LLC
A61K31/5377A61K9/0014A61P17/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,667,576
App. No.
17/963,502
Filed
Oct 11, 2022
Granted
Jun 30, 2026
Kind
B2
Art Unit
1614
USPC
514/235.5
Abstract

The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.

Claims (59)

1 . A method of treating actinic keratosis comprising topically administering to a subject in need thereof a therapeutically effective amount of a compound of the following structure:

to an affected area of the subject, wherein the therapeutically effective amount is 0.5 mg to 4 mg in a daily single dose unit and wherein the affected area is 0.1 cm 2 to 100 cm 2 .

2 . The method of claim 1 , wherein the therapeutically effective amount is 0.5 mg to 3 mg.

3 . The method of claim 1 , wherein the therapeutically effective amount is 1 mg to 2.5 mg.

4 . The method of claim 1 , wherein the therapeutically effective amount is 1.3 mg to 2.5 mg.

5 . The method of claim 1 , wherein the therapeutically effective amount is 2.5 mg.

6 . The method of claim 1 , wherein the therapeutically effective amount is 1 mg to 4 mg.

7 . The method of claim 1 , wherein the therapeutically effective amount is 3 mg to 4 mg.

8 . The method of claim 1 , wherein the therapeutically effective amount is 3 mg.

9 . The method of claim 1 , wherein the affected area is 1 cm 2 to 100 cm 2 .

10 . The method of claim 1 , wherein the affected area is 5 cm 2 to 100 cm 2 .

11 . The method of claim 1 , wherein the affected area is 10 cm 2 to 100 cm 2 .

12 . The method of claim 1 , wherein the affected area is 100 cm 2 .

13 . The method of claim 7 , wherein the affected area is 1 cm 2 to 100 cm 2 .

14 . The method of claim 7 , wherein the affected area is 5 cm 2 to 100 cm 2 .

15 . The method of claim 7 , wherein the affected area is 10 cm 2 to 100 cm 2 .

16 . The method of claim 7 , wherein the affected area is 25 cm 2 to 100 cm 2 .

17 . The method of claim 7 , wherein the affected area is 100 cm 2 .

18 . The method of claim 1 , wherein the affected area is 0.1 cm 2 to 25 cm 2 .

19 . The method of claim 1 , wherein the affected area is 1 cm 2 to 25 cm 2 .

20 . The method of claim 1 , wherein the affected area is 5 cm 2 to 25 cm 2 .

21 . The method of claim 1 , wherein the affected area is 10 cm 2 to 25 cm 2 .

22 . The method of claim 1 , wherein the affected area is 25 cm 2 .

23 . The method of claim 5 , wherein the affected area is 1 cm 2 to 25 cm 2 .

24 . The method of claim 5 , wherein the affected area is 5 cm 2 to 25 cm 2 .

25 . The method of claim 5 , wherein the affected area is 10 cm 2 to 25 cm 2 .

26 . The method of claim 5 , wherein the affected area is 25 cm 2 .

27 . The method of claim 1 , wherein the therapeutically effective amount is 0.035 mg/cm 2 .

28 . The method of claim 1 , wherein the therapeutically effective amount is 0.1 mg/cm 2 .

29 . The method of claim 1 , wherein the compound is administered once a day.

30 . The method of claim 5 , wherein the compound is administered once a day.

31 . The method of claim 7 , wherein the compound is administered once a day.

32 . The method of claim 17 , wherein the compound is administered once a day.

33 . The method of claim 26 , wherein the compound is administered once a day.

34 . The method of claim 27 , wherein the compound is administered once a day.

35 . The method of claim 28 , wherein the compound is administered once a day.

36 . The method of claim 1 , wherein the compound is administered once a day for 5 consecutive days.

37 . The method of claim 5 , wherein the compound is administered once a day for 5 consecutive days.

38 . The method of claim 7 , wherein the compound is administered once a day for 5 consecutive days.

39 . A method of treating actinic keratosis comprising topically administering to a subject in need thereof a therapeutically effective amount of a compound of the following structure:

to an affected area of the subject, wherein the therapeutically effective amount is 0.5 mg to 4 mg and wherein the affected area is 0.1 cm 2 to 100 cm 2 , wherein the affected area is the face or scalp.

40 . The method of claim 39 , wherein the therapeutically effective amount is 3 mg to 4 mg, the affected area is 100 cm 2 , and the compound is administered once a day for 5 consecutive days.

41 . The method of claim 39 , wherein the therapeutically effective amount is 2.5 mg, the affected area is 25 cm 2 , the compound is administered once a day for 5 consecutive days.

42 . The method of claim 39 , wherein the therapeutically effective amount is 0.035 mg/cm 2 and the compound is administered once a day for 5 consecutive days.

43 . The method of claim 39 , wherein the therapeutically effective amount is 0.1 mg/cm 2 and the compound is administered once a day for 5 consecutive days.

44 . The method of claim 1 , wherein the therapeutically effective amount is 3 mg to 4 mg, the affected area is 100 cm 2 , and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days.

45 . The method of claim 1 , wherein the therapeutically effective amount is 2.5 mg, the affected area is 25 cm 2 , and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days.

46 . The method of claim 1 , wherein the therapeutically effective amount is 0.035 mg/cm 2 , and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days.

47 . The method of claim 1 , wherein the therapeutically effective amount is 0.1 mg/cm 2 , and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days.

48 . The method of claim 1 , wherein the therapeutically effective amount is 0.035 mg/cm 2 , the affected area is the face or scalp and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days.

49 . The method of claim 1 , wherein the therapeutically effective amount is 0.1 mg/cm 2 , the affected area is the face or scalp and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days.

50 . The method of claim 1 , wherein the compound is topically administered to an affected area on the face or scalp of a subject in need thereof, once a day for 5 consecutive days at a single-dose unit of 2.5 mg to 4 mg over an affected area of 1 cm 2 to 100 cm 2 .

51 . The method of claim 50 , wherein the single-dose unit is 3 mg to 4 mg.

52 . The method of claim 51 , wherein the affected area is 1 cm 2 to 25 cm 2 .

53 . The method of claim 51 , wherein the affected area is 25 cm 2 to 100 cm 2 .

54 . The method of claim 50 , wherein the single-dose unit is 2.5 mg.

55 . The method of claim 54 , wherein the affected area is 1 cm 2 to 25 cm 2 .

56 . The method of claim 54 , wherein the affected area is 25 cm 2 to 100 cm 2 .

57 . The method of claim 54 , wherein the affected area is 100 cm 2 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2022
From: KWAN, MIN-FUN RUDOLF; LAU, JOHNSON YIU-NAM; KRAMER, E. DOUGLAS; CUTLER, DAVID LAWRENCE; FANG, JANE
To: ATHENEX, INC.
Reel/Frame 061459/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2022
From: ATHENEX, INC.
To: ATNX SPV, LLC
Reel/Frame 061459/0166 →
Continuity (4)
Continuation 16804092 · Feb 28, 2020
Continuation 15918100 · Mar 12, 2018
Provisional Application 62469889 · Mar 10, 2017
Related Publication 20230172942A1 · Jun 8, 2023
References Cited (49)
US 7300931B2 · Hangauer · 2007 [cited by applicant]
US 7538252B2 · Ossovskaya et al. · 2009 [cited by applicant]
US 7851470B2 · Hangauer et al. · 2010 [cited by applicant]
US 7935697B2 · Hangauer · 2011 [cited by applicant]
US 7939529B2 · Hangauer et al. · 2011 [cited by applicant]
US 7968574B2 · Hangauer · 2011 [cited by applicant]
US 8003641B2 · Hangauer · 2011 [cited by applicant]
US 8236799B2 · Hangauer · 2012 [cited by applicant]
US 8293739B2 · Hangauer et al. · 2012 [cited by applicant]
US 8309549B2 · Hangauer · 2012 [cited by applicant]
US 8569320B2 · Melzer et al. · 2013 [cited by applicant]
US 8598169B2 · Hangauer, Jr. · 2013 [cited by applicant]
US 8901297B2 · Hangauer et al. · 2014 [cited by applicant]
US 8980890B2 · Hangauer · 2015 [cited by applicant]
US 9556120B2 · Hangauer · 2017 [cited by applicant]
US 9580387B2 · Hangauer · 2017 [cited by applicant]
US 9655903B2 · Hangauer · 2017 [cited by applicant]
US 10196357B2 · Hangauer · 2019 [cited by applicant]
US 10323001B2 · Hangauer · 2019 [cited by applicant]
US 10617693B2 · Kwan et al. · 2020 [cited by applicant]
US 20100249130A1 · Hangauer · 2010 [cited by applicant]
US 20110021555A1 · Nordsiek et al. · 2011 [cited by applicant]
US 20130197089A1 · Warnecke · 2013 [cited by applicant]
US 20130210822A1 · Hangauer et al. · 2013 [cited by applicant]
US 20140256667A1 · Moy · 2014 [cited by applicant]
US 20170101378A1 · Hangauer et al. · 2017 [cited by applicant]
US 20170196874A1 · Hangauer · 2017 [cited by applicant]
WO 2008082637 · 2008 [cited by applicant]
WO 2008144045 · 2008 [cited by applicant]
WO 2010135429 · 2010 [cited by applicant]
WO 2014004376 · 2014 [cited by applicant]
Kinex Pharmaceuticals; “Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study”; 2015; https://www.prnewswire.com/news-releases/kinex-pharmaceuticals-… [cited by examiner]
“A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1 % on AK on Face or Scalp (AK004) NCT03285490”, ClinicalTrials.gov, Sep. 18, 2017. [cited by applicant]
“Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)”, Cision PR Newswire, Jul. 24, 2014, pp. 1-3. [cited by applicant]
“General Guidelines for Clinical Evaluation of New Drugs” (PAB/NDD Notification No. 43), addressed to Directors of Health Departments of Prefectural Governments, Pharmaceutical Affairs Bureau, Ministry of Health and Wel… [cited by applicant]
“Kinex receives FDA approval to begin Phase I study ofKX2-391 ointment for actinic keratosis” 2014, 2 pages. Retrieved from Internet: (URL: https://www.news-medical.net/news/20140725/Kinex-receives-FDA-approval-to-begin… [cited by applicant]
FDA Accepts Investigational New Drug Application for KX2-391 Ointment for the Treatment of Actinic Keratosis, Zhao Wenli, Journal of International Pharmaceutical Research, vol. 41, No. 5, p. 584. [cited by applicant]
Gail M. et al., “Dose Finding in Drug Development”, Statistics for Biology and Health, Springer Science+Business Media, Inc., 2006, Preface. [cited by applicant]
Kharkevich Pharmacology, 10th ed. M.: GEOTAR-Media, 2010, p. 73-74. [cited by applicant]
Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study, Jan. 20, 2015. [cited by applicant]
Kinex Pharmaceuticals: “Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)”, Buffalo, N.Y., Jul. 24, … [cited by applicant]
Mayo Clinic, “Actinic keratosis”, “www.mayoclinic.org/diseases-conditions/actinic-keratosis/symptoms-causes/syc-20354969”, Mar. 7, 2018, 3 pages; downloaded Jun. 23, 2018. [cited by applicant]
Mironov, ed. “Guidelines for conducting preclinical studies of drugs” Part One, 2012, 944 pages. [cited by applicant]
NCT02337205 “Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis”, 2015, ClinicalTrials.gov, 18 pages. [cited by applicant]
NCT02838628 “Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp”, 2016, ClinicalTrials.gov, 33 pages. [cited by applicant]
Savary, J. et al. “The right dose in the right place: an overview of current prescription instruction and application modalities for topical psoriasis treatments”, JEADV, 2005, 19, 14-17. [cited by applicant]
Zhulenko V.N., Gorshkov G.I. Pharmacology. M.: KolosS, 2008, pp. 34-35. [cited by applicant]
Blauvelt, et al., “Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis” The New England Journal of Medicine, 384;6, 2021, pp. 512-520. [cited by applicant]
Bhatia, et al., “Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study” JAAD Int, vol. 17, 2024, pp. 6-14. [cited by applicant]